Method of treating rheumatoid arthritis

FIELD: medicine.

SUBSTANCE: according to the method, the affected joints are exposed. The exposure is performed by electrophoresis with 2% pentoxifylline. The pentoxifylline solution is introduced from an anode at current intensity 15 mA. The 15-minute introduction is performed at current density 0.05-0.1 mA/cm2. The therapeutic course is 10 procedures.

EFFECT: method is non-invasive, easy to implement; it reduces the length of treatment.

1 ex

 

The invention relates to medicine, namely to rheumatology, and can be used for complex treatment of patients with rheumatoid arthritis.

Rheumatoid arthritis is a chronic immunopositive disease that affects how the synovial membrane of the joints and visceral systems (Rheumatology: Clinical guidelines / Ed. by Acad. The RAMS E. L. Nasonov. - 2nd ed., Corr. and supplementary): GEOTAR-Media, 2011. - S. 90-230). Immunopositive defeat of the circulatory system in patients with rheumatoid arthritis affects the vessels of medium and small-caliber, leading to vasculitis and depletion of tissue perfusion and microcirculation (Radenska-Lapovok, S., Nasonova Century A. Vasculitis and vasculopathy: common features and characteristics. Therapeutic archive, 1998, No. 11, S. 58-59).

Pressing is a method of treatment of rheumatoid arthritis: a non-invasive, high therapeutic potency, ease of use, requiring minimal amount of time.

There is a method of treatment of rheumatoid arthritis plaster with magnetic powder of rare-earth metals, nanopowder-producition infrared radiation in the far infrared region of the spectrum (Nanoplat-Forte, LLC Nanotek Pharma, Russia), is applied to the area affected joints for 12 hours (ostack N. A. Nanotechnology in optimizing for local treatment of pain syndromes / N. A. Shostak, A. A. Klimenko // Medical Council. - 2012. No. 8. - S. 1-6).

The disadvantages of this method are:

1. Adhesive transdermal patch can cause allergic reactions.

2. The procedure is carried out for a long time (12 hours).

3. After the procedure, the level of microcirculation quickly (within 10-15 minutes) back to the original, because the body is not created depot medicinal substance.

The closest achieved technical result is a method of treating rheumatoid arthritis by administration of levamisole. A solution of levamisole moisten strip of flannel and strengthen them in region XII breast - I of the lumbar vertebrae on either side of the spine; metal electrodes connected to a terminal of the positive pole of the DC source, and a negative with a similar gasket strengthen in nadupanou area. Levamisole administered bipolar. The current density of 0.05-0.1 mA/cm2the duration of exposure to 20 minutes for a treatment course of 10 treatments. One day procedure release transabdominal, and on another day on the affected joints. To do this, the flannel strip moistened with a solution of levamisole, strengthen on both sides of the joint and carry out electrophoresis of bipo the Jarno. The current density of 0.05-0.1 mA/cm2the duration of exposure to 20 minutes for a treatment course of 10 treatments (Patent SU 1178454, A1, 15.09.1985).

The disadvantages of this method are:

1. Enter the drug levamisole has no angioprotective and vasodilator effects.

2. Enter the drug levamisole improves microcirculation.

The authors proposed an efficient method for the treatment of rheumatoid arthritis with a high therapeutic efficacy, ease of use, requiring minimal time, non-invasive.

The technical result of the proposed method is to increase the effectiveness of treatment of rheumatoid arthritis.

The technical result is achieved by conducting electrophoresis 2% solution of pentoxifylline, which is injected from the anode, at an amperage of 15 mA.

The method is as follows.

On the area affected joints impose wipes moistened with 2% solution of pentoxifylline (Trental, Sanofi-aventis, France). Using carbon electrodes. Electrophoresis is carried out at a current density of 0.05-0.1 mA/cm2current 10-15 mA, duration 15 minutes. The drug is injected from the anode. Procedures carried out daily at the rate of 10 procedures.

Equipment and materials: the "Thread-1" (factory EMA, , Ekaterinburg, Russia), three gauze pads, two toconsume the electrode, 5 milliliters of pentoxifylline (Trental, Sanofi-aventis, France) in the form of 2% solution in water for injection 1 procedure.

Indications: rheumatoid arthritis, articular form.

Known use of the drug for the treatment of rheumatoid arthritis only by intravenous infusion and destination in tablet form.

Contraindications: decompensation of diabetes, cardiovascular disease, cancer, pregnancy, epilepsy, progressive synovitis, the rapid development of functional insufficiency, early post-operative period.

Clinical example. Patient K., 67 years old, was hospitalized in the city of rheumatic Central Barnola diagnosed with rheumatoid arthritis, articular form, seropositive, II rentgenologicheski stage, activity-II, failure of function of the joints-II. Upon receipt complained of pain in the joints of the fingers, morning stiffness for 3 hours, numbness and cold skin of the fingers in the cold and the excitement. In the hospital the patient assigned to standard therapy: methotrexate 15 mg per week, Ketoprofen 100 milligrams a day, folic acid 3 milligrams per day. When conducting pharmacological therapy received slabopolozhitelnym clinical dynamics, however, persisted morning stiffness for 2 h the owls, severe pains in the joints of the hands at rest (up to 70 points on the visual analogue scale), numbness and cold fingers with excitement and cold. The patient is directed to rehabilitation using electrophoresis of pentoxifylline. After 10 treatments, the time of morning stiffness in the joints of the hands significantly decreased to 30 minutes, pain in the joints of the hands decreased (up to 30 points on the visual analogue scale). Cooling of the skin of the fingers and blanching when exposed to low ambient temperature and emotional factors cropped.

The inventive method of treatment of rheumatoid arthritis electrophoresis with pentoxifylline has a high therapeutic efficacy, ease of use, requires minimal time, non-invasive, which allows to increase the effectiveness of treatment.

The inventive method will be widely used in rheumatology departments of hospitals.

The method of treatment of rheumatoid arthritis, including the impact on the affected joints by carrying out electrophoresis at the current density of 0.05-0.1 mA/cm2within 15 minutes, in the course of 10 treatments, characterized in that the conducting electrophoresis 2% solution of pentoxifylline, which is injected from the anode, at an amperage of 15 mA.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents pharmaceutical depot, made for introduction by intra-articular injection into joint of subject, suffering from osteoarthritis, which contains microparticles or nanoparticles, composed of N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-[pyridin-2-ylmethoxy)benzamide or its pharmaceutically acceptable salt and biodegradable copolymer lactic acid-glycolic acid.

EFFECT: invention provides controlled release of active agent and long action without toxic side effects.

13 cl, 5 ex, 3 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention represents a drug for treating osteoarthrosis presented as a soft dosage form, containing glucosamine and methyl salicylate as active substances, and additive agents.

EFFECT: enhanced anaesthetic action and lower toxicity of methyl salicylate.

10 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: composite application of therapeutic preparations is combined with a laser therapy. A basic anti-inflammatory preparation is presented by methotrexate administered subcutaneously in a dose of 15mg once a week, and folic acid administered orally in a dose of 5mg a week. Movalis is additionally prescribed in the form of intramuscular injections in a dose of 15mg once a day. The laser therapy is differentiated depending on a degree of the disease, a degree of endothelial dysfunction manifestation, namely a von Willebrand factor (vWF), haemostasis system activity indices, namely activated partial thromboplastin time (APTT), prothrombin time (PTT), thrombin clotting time (TCT), antithrombin III (AT III), protein C. If observing the degree I of the disease, APTT 30.6±1.5 sec or more, PTT 19.2±0.9 sec or more, TCT 15.1±0.7 sec or more, AT III 92.8±7.6% or more, protein C 0.92±0.02 or more, vWF 108.9±9.6% or less, 6-8 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at a light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. The degrees II and III of the disease, APTT 22.2±5.5 sec or less, PTT 12.8±1.7 sec or less, TCT 11.2±0.9 sec or less, AT III 85.4±1.1% or less, protein C 0.84±0.02 and less, vWF 133.5±2.2% or more, require performing 10 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at the light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day.

EFFECT: method enables reducing the clinical manifestations of the disease, provides higher effectiveness of the drug therapy by involving the pathological processes in the haemostasis system.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula IV, VIII-A and X, and to their pharmaceutical acceptable salts possessing the inhibitory activity on PI3-kinase (phosphoinositide-3-kinase). In compounds of formula IV and IX and Wd is specified in a group consisting of, , , and each of which can be substituted. In formula VIII-A, the group Wd represents the group or , wherein Ra is hydrogen, R11 is amino; in compound IV, Wa2 represents CR5; Wa3 represents CR6; Wa4 represents N or CR7; in compound IX, Wa1 and Wa2 independently represent CR5, N or NR4, and Wa4 independently represents CR7 or S, wherein no more than two neighbouring atoms in a ring represent atom or sulphur; Wb5 represents N; B represents a grouping of formula II, as well as in case of compound IV, B means C1-C10alkyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl having one to six ring heteroatoms specified in N, O and S; in case of compound IX, B also means C1-C10alkyl, C3-C10cycloalkyl or 6-merous heterocycloalkyl having nitrogen atom; Wc represents C6-C10aryl or 5-18-merous heteroaryl having one or more ring heteroatoms specified in N, O and S, or phenyl or 6-merous heteroaryl respectively is equal to an integer of 0, 1, 2, 3 or 4; X is absent or represents -(CH(R9))z-, respectively; z is equal to 1; Y is absent. The other radical values are specified in the patent claim.

EFFECT: compounds can be used for treating such diseases, as cancer, bone disorders, an inflammatory or immune disease, diseases of the nervous system, metabolic disorders, respiratory diseases, thrombosis or cardiac diseases mediated by PI3-kinase.

68 cl, 11 dwg, 7 tbl, 55 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of general formula [1] or their pharmaceutically acceptable salts, which possess properties of an inhibitor of the JAK2 thyrokinase activity. In general formula radicals are selected from group (I) or (II). In group (I) X represents CH or N; R1 represents a halogen atom and R2 represents H, a halogen atom, CN, or is selected from the groups of formulas

,

or a group -ORP or 5-6-membered heteroaryl, containing 1-4 nitrogen atoms and optionally additionally containing an oxygen or sulphur atom or containing an oxygen atom as a heteroatom, optionally substituted; or (II) X represents -CRA; and RA represents a group of formula , RB represents (a) amino, optionally substituted with one or two groups, selected from the group, consisting of C1-6alkyl, C3-6cycloalkyl, (C3-6cycloalkyl)C1-6alkyl and C1-3alcoxyC1-3alkyl, (b) C1-3alcoxy, (c) hydroxy or (d) a 5-6-membered saturated cyclic amino group, which additionally can contain a heteroatom, selected from an oxygen atom; R1 represents a halogen atom and R2 represents H; R3 -R5 have values given above. Other values of the radicals are given in the invention formula.

EFFECT: compounds can be applied for the prevention or treatment of cancer, for instance hematologic cancer disease or a solid form of cancer, inflammatory disorder, for instance, rheumatoid arthritis, inflammatory intestinal disease, osteoporosis or multiple sclerosis and angiopathy, for instance, pulmonary hypertension, arteriosclerosis, aneurism or varicose veins.

14 cl, 19 tbl, 234 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises intravenous injection of 3-5.5% aqueous solution of lithium chloride based on 2.5-3.5 mmol/kg of animal body weight, and additionally subcutaneously 10-30% aqueous solution of polyethylene glycol-4000 based on 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: increased efficiency and simplification of the method.

4 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises administering the medicinal product, and the medicinal product is used as 10-30% aqueous solution of polyethylene glycol-4000, which is administered subcutaneously in an amount of 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: improvement of efficiency of the method.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), possessing an activity with respect to cytokines, versions of based on them pharmaceutical compositions and their application. Formula (I) compounds can be applied for treatment or prevention asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis or gouty arthritis. In general formula (I) L is selected from the group, consisting of -C(O)-, -CH2-, Ar1 represents a mono-, di- or trisubstituted phenyl ring, where substituents are independently selected from the group, consisting of a halogen and -C1-4alkyl; Ar2 represents an optionally substituted thiadiazolyl ring, where the substituent represents -C1-4alkyl, -C3-5cycloalkyl, -methylcyclopropyl, phenyl or a 5- or 6-membered monocyclic heteroaromatic ring or a bicyclic heteroaromatic ring with 9 or 10 atoms, with the said heteroaromatic ring containing 1, 2 or 3 heteroatoms, selected from the group, consisting of S, O and N, where the said phenyl or heteroaromatic ring is optionally mono- or disubstituted with substituents, independently selected from the group, consisting of a halogen, -C1-6alkyl, optionally substituted with 1-4 fluorine atoms, -O-C1-6alkyl, -CF3 and oxo.

EFFECT: increased efficiency of the application of the compounds.

16 cl, 1 tbl, 46 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating patients with epicondylitis. That is ensured by applying a complex of measures, in particular a restraint of motions in the involved segment, physiotherapy and drug treatment. A pain syndrome is pre-evaluated by a visual analogue scale (VAS). A proximal forearm is immobilised with an epicondylic bandage in the daytime for 7-10 days in sportsmen, and for 2-3 weeks in common patients. Therapeutic exercises (TE) are prescribed from the first day of treatment. The first part of TE consisting of isometric and static exercises aiming at strengthening arm muscles is done before noon. The second part of TE comprising relaxing exercises is performed in the late afternoon or after any physical loads. The patient continues with the therapeutic exercises after the bandage is removed and to be used for professional or sports loads only. Electric stimulation is conducted daily for 7-10 days with using TENS apparatus or its analogues generating electrical signals covering the enthesis and the involved forearm muscles. Arthrofoon is administered with underlying electric stimulation. If the pain syndrome value according to the VAS is less than 4 points, the preparation is administered as a monotherapy in a dose of 4 weeks a day for three months. If the pain syndrome according to the VAS is more than 4 points, Arthrofoon is administered in a dose of 8 tablets a day in a combination with a selective non-steroid anti-inflammatory preparation in a therapeutic dose for no more than 10 days. The therapeutic regimen also contains Sirdalud 2-4 mg one hour before bedtime for 2 weeks. There are also administered vasodilators improving microcirculation of the involved segment, intramuscularly for 10 days. The therapeutic complex is also added with Milgamma B 2 ml, 5 injections, and another 5 injections triduan. Wobenzyme is administered for 3-4 weeks. Calcemine or Calcemine-advance, the preparations of calcium are administered for six months. The therapeutic course according to the presented regimen is repeated half a year later. The physical exercising for the arm muscles strengthening are to be further done two or three times a week on the average for min. 30 minutes for the life term if suffering high loads or doing any top-class sports for the purpose of maintaining the forearm tonus. The segment of interest is fixed with an orthesis when suffering a load. The therapy with the TENS or similar apparatus of the forearm muscles of interest and the enthesis follow a pronounced load 2-3 hours before bedtime and shall be accompanied with a session of relaxing exercises.

EFFECT: method provides the evident and stable clinical effect characterised by the complete recurrence-free recovery by the physical restoration of the tissue structure within the inflammation with the high quality of life and a surgical intervention avoided.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: device is presented in the form of a medical syringe comprising a cylindrical body, a female shell, an in-built primary piston provided with a rod, a front with a needle and back lids attached on end faces of the cylindrical body, a power supply arranged under the shell, representing a galvanic battery and connected to a push button and two conductive electrodes each of which is presented in the form of a semi-cylindrical surface prepared by conductive material deposition on an inner surface of the cylindrical body, and electrically isolated from the other by two non-conductive spaces along the generator lines of the cylindrical body on opposite ends of the diameter. In front of the primary piston, the cylinder body comprises an additional piston provided with perforations axes of which have various angles to an axis of symmetry of the rod, and the rod of the additional piston coaxial with a hollow rod of the primary piston. The cylindrical body has a front end face of a circle with a hole in the middle with additional surfaces of the electrodes prepared by conductive material deposition on the inner annular surface, each of which is a semi-ring and is electrically isolated from the other one by the non-conductive space to the diameter of the circle. The front end face of the primary rod comprises a notch having a size fitting the size of the additional rod; the shell is arranged on the posterior portion of the cylindrical body and has a perforation facing the power source in the form of a light diode connected to the power source in parallel to the electrodes.

EFFECT: using the invention enables providing the higher quality of the prepared liquid drug from electrophoresis.

13 dwg

FIELD: medicine.

SUBSTANCE: course of the complex exposure of audio-, video- and reflex therapy with an unconscious suggestion is carried out. That is preceded by administering epitalamine 10 mg dissolved in a physiological solution 5 ml by electrophoresis. Administration is binasal from a positive pole into a patient's nasal passages in a number of 10-15 procedures. The second electrode is placed on the occipital lobe or the cervicothoracic spine. The complex exposure involves watching video information, listening to audio musical information with an introduced suggestive relaxing fable repeated every 1 minute, and exposing through electrodes provided on the skin projections in biologically active points within the lesions to electrical current a spectral structure of which is formed by the same musical signal by an electric musical massager. That is combined with the electric stimulation of the reflex areas arranged in the lesions if feeling itching therein. The exposure length is 45-60 minutes, domiciliary in any time of the day, daily for 3-4 weeks.

EFFECT: effective exposure on the mechanisms eliminating or relieving the itching intensity by preparing the neuroregularoty structures of the patient's central nervous system by the following therapeutic stage of the two-staged integrated exposure according to the presented regimen.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely ophthalmology. The method involves a transepithelial corneal collagen crosslinking. That is preceded with a single bath electrophoresis with 1% riboflavin mononucleotide. That is ensured by an initial current of 0.2 mA to be increased gradually to 1 mA, at a pitch of 0.2 mA for 2 minutes. That is followed by an ultraviolet corneal exposure. The exposure is conducted at wave length 370 nm, power 3 mWt/cm2 and combined with instillation of a riboflavin solution. The solution contains 0.1% riboflavin mononucleotide and 20% dextran.

EFFECT: method provides more effective riboflavin delivery to the corneal stroma for one procedure providing the intraocular protection against ultraviolet light.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology, physiotherapy. The method involves endonasal cortexin electrophoresis with underlying glaucoma therapy. Cortexin is administered from an anode. For this purpose, a bifurcated positive electrode is applied on cotton swabs wetted in a drug solution. The electrodes are introduced into the middle nasal passages. An indifferent electrode is fixed with elastic bandages on the skin of the posterior surface of the neck. The first two procedures require galvanisation at current intensity 0.5 mA for 7 minutes. That is followed by medical cortexin electrophoresis from 3rd to 12th sessions. The current intensity from the 3rd to 5th sessions is 1 mA for 10 minutes. The current intensity from the 6th to 12th sessions is 1 mA for 15 minutes. The procedures are performed every second day.

EFFECT: method improves the clinical functional, perimetric and electrophysiological characteristics of the visual analyser, slows down the disease development and improves the patient's quality of life.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely rheumatology, physiotherapy. The method involves drug-induced and drug-free methods of treating. In addition, the area of two affected symmetrical joints is applied with the preparation Biol in a combination with the exposure to high-tone therapy. The length of procedures is 1 to 4-5 to 30 minutes per each joint. Starting from the 4-5th to 8-10th procedure, the length of procedures is 20 minutes per each joint. The procedures are daily. The therapeutic course is 8-10 procedures.

EFFECT: method provides higher therapeutic effectiveness ensured by improved microcirculation, ensured anaesthetic effect, reduced drug-induced load.

1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely otorhinolaryngology and may be used for various ear diseases. That is ensured by presenting the systems for electrophoresis drug delivery to a human or animal ear drum. The system contains an ear tampon having distal and proximal portions with a tube passing in between and having a smaller rigidity as compared to the proximal and distal portions of the ear tampon. One flexible sealing element extending from an external surface of the tube and closer to a distal end than to a proximal one. An electrode consisting of an extended shaft, a tip having a greater diameter as compared to the trunk. The electrode is placed inside of the tube of the ear tampon from the retracted position wherein a fluid can flow in the tube round the electrode into the extended position, wherein the electrode tip is in contact with the internal surface of the tube thereby preventing the fluid flow in the tube. The system can also comprise two flexible sealing members integrated with the extended tube. There are also presented methods for anaesthetising the ear drum by using the given system. There are presented kit for anaesthetising comprising the drug delivery system and controller coupled with the electrode.

EFFECT: inventions provide the drug delivery, including anaesthetics into the patients being in the vertical position, due to a possibility to retain the solution hermetically in the external ear canal with no additional conditions provided.

23 cl, 12 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to - physiotherapy, to infectious diseases. The method involves the integrated use of drug preparations, magnetic and laser therapy. The laser therapy is differentiated depending on the severity, modified leukocytal intoxication index (mLII), malondialdehyde (MDA), lipid hydroperoxide (LHP), antioxidant activity (AOA), interleukin-1β (IL-1β), tumour necrosis factor (TNF-α). The mild severity, mLII within the range of 2.8±0.09-3.44±0.07, MDA 3.7±0.08-4.2±0.07mcm/ml, LHP 10.1±0.1-11.3±0.09 mcm/ml, AOA 0.489±0.005-0.390±0.007, IL-1β 25.3±0.5-26.71±0.3 pg/ml; TNF-α 37.1±0.5-45.7±0.8 pg/ml require the daily percutaneous exposure to a constant magnetic field and low-intensity laser light of power 55 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours. The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 60 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power min. 5 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by a light guide tip. The length of the exposure is 120 minutes. The therapeutic course consists of 5 procedures. The moderate severity, mLII 4.18±0.08-6.06±0.07, MDA 4.9±0.03-5.6±0.02 mcm/ml, LHP 12.3±0.08-14.7±0.07 mcm/ml; AOA 0.345±0.007-0.315±0.006, IL-1β 27.1±0.2-28.1±0.1 pg/ml, TNF-α 57.7±0.9-72.1±0.5 pg/ml requires the daily percutaneous exposure to the constant magnetic field and low-intensity laser light of power 60 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours. The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 90 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power 7 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by the light guide tip. The length of the exposure is 150 minutes. The therapeutic course is 7 procedures. The severe condition, mLII 7.76±0.08-8.06±0.07, MDA 7.1±0.03-11.6±0.02 mcm/ml, LHP 16.3±0.08-19.7±0.07 mcm/ml; AOA 0.310±0.007-0.294±0.006, IL-1β 30.1±0.2-31.1±0.1 pg/ml, TNF-α 76.7±0.9-85.1±0.5 pg/ml requires the daily percutaneous exposure to the constant magnetic field and low-intensity laser light of power 60 mWt, wave length 0.89 mcm, pulse frequency 80 Hz in the morning hours The contact scanning exposure covers a projection of thymus, regional lymphatic nodes and great vascular pedicle. The length of the exposure makes 120 seconds per each region. Then, an inflammatory centre is exposed to pulse red light of wave length 0.65 mcm, output pulse power 9 Wt, pulse frequency 80 Hz, modulation frequency of light-emitting diodes 8 Hz generated by the light guide tip. The length of the exposure makes 180 seconds. The therapeutic course consists of 9 procedures. For the first five days, all the patients are prescribed with heparin electrophoresis by common technique during afternoon.

EFFECT: method reduces a rate of recurrence.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely neural diseases, neurosurgery, traumatology. A neck surface is exposed to autoresonant red emission in a projection of carotid sinus at wave length 0.63-0.66 mcm, power 24-26 mWt for 7-10 minutes and to infrared emission at wave length 0.87-0.89 mcm, power 9-10 Wt for 10-15 minutes. That is followed by pharmacological neuroprotection by intranasal electrophoresis with neuroprotective preparation at current intensity 0.5-2.0 mA for 15-20 minutes. The treatment is started from the third post traumatic day. The first therapeutic day required the exposure to red laser light followed by a 15-20-minute pause and the intranasal electrophoresis in the morning with the exposure to red laser light in the evening. On the second therapeutic day, the exposure to red laser light is performed in the morning, and in the evening the same is followed by a 15-20-minute pause and the intranasal electrophoresis. The treatment is conducted within 14-20 days.

EFFECT: method enables reducing the length of traumatic intracranial haematoma resolution ensured by the synergetic effect of the red and infrared laser light and therapeutic preparations.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and medical equipment, namely to apparatuses used in oncology and physiotherapy. The apparatus comprises two electrodes mounted in cavities of dielectric cup-shaped body connected to a UHF unit, each body of which is provided with an additional mesh electrode of a graphitised electrically conductive cloth with a lining adjoining thereto and impregnated with a drug substance. The mesh electrode is shaped and sized after the main electrode; it is parallel to the main electrode, separated therefrom with a dielectric lining and connected to a DC power source. An outer surface of each body comprises equispaced ribs with through holes flushes for flexible lightguide in the number of 4 to 10, assembled in a common cable and connected to a laser light source generating laser light to cover the tumour from both sides.

EFFECT: using the invention enables extending the physiotherapeutic functions of the UHF hyperthermia apparatuses.

4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely physiotherapy, otorhinolaryngology. The method involves the endonasal drug administration by electrophoresis. For electrophoresis, two paired U-cathodes are placed around the right and left ears. The drug preparations are administered by a wet nonwoven material. The endonasal electrodes (anodes) are wrapped with the nonwoven material of surface density 40-60 g/m2. The material of the one electrode is coated with a composition of sodium alginate and hydrocortisone, while another one - with a composition of sodium alginate and mexidol in a therapeutically effective amount. The nonwoven material of the surface density 160-180 g/m2 of the form congruent to the electrodes is laid under the U-cathodes. The material is coated with the composition of sodium alginate and urea in a therapeutically effective amount. The procedures are daily. The nonwoven material is kept after the procedure for another 10 - 20 minutes. The therapeutic course is 5-10 procedures.

EFFECT: method provides the comfortable procedure ensured by the soft plastic form of the non-woven material, mucus absorbability from the nasal passages onto the sodium alginate, improved nasal breathing, loss of the conductive component with the objective hearing improve.

2 ex

FIELD: food industry.

SUBSTANCE: biologically active food additive strengthening the organism adaptive power and body defences and having anti-inflammatory and antioxidant activity contains vegetal origin components represented by a complex extract of devil's-club root, Rhaponticum carthamoides root, Hedysarum neglectum Ledeb root, celery roots and leaves, rhodiola rosea root, Japanese angelica tree roots, boschniakia rossica roots, Hungarian sainfoin herb, magnolia-vine fruits; additionally the additive contains chitosan, trepang fermentative hydrolysate, ascorbic acid, taurine, glutathione, nicotinamide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, anhydrous calcium chloride, magnesium chloride, zinc chloride, bee honey at preset ingredients ratio.

EFFECT: biologically active food additive promotes effective strengthening of the organism adaptive power and body defences and human aging retardation.

4 tbl, 6 ex

Up!